Biocept (BIOC) & Miragen Therapeutics (MGEN) Head-To-Head Review

Biocept (NASDAQ: BIOC) and Miragen Therapeutics (NASDAQ:MGEN) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, risk, dividends, profitability, valuation, earnings and institutional ownership.

Risk and Volatility

Biocept has a beta of 1.77, indicating that its stock price is 77% more volatile than the S&P 500. Comparatively, Miragen Therapeutics has a beta of 1.33, indicating that its stock price is 33% more volatile than the S&P 500.

Earnings & Valuation

This table compares Biocept and Miragen Therapeutics’ gross revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Biocept $5.07 million 3.36 -$21.61 million ($0.79) -0.32
Miragen Therapeutics $4.00 million 49.18 -$26.51 million ($1.38) -4.72

Biocept has higher revenue and earnings than Miragen Therapeutics. Miragen Therapeutics is trading at a lower price-to-earnings ratio than Biocept, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of current recommendations for Biocept and Miragen Therapeutics, as reported by

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Biocept 0 0 2 0 3.00
Miragen Therapeutics 0 1 8 0 2.89

Biocept currently has a consensus target price of $1.25, indicating a potential upside of 400.00%. Miragen Therapeutics has a consensus target price of $17.19, indicating a potential upside of 163.61%. Given Biocept’s stronger consensus rating and higher probable upside, analysts clearly believe Biocept is more favorable than Miragen Therapeutics.

Institutional & Insider Ownership

8.7% of Biocept shares are held by institutional investors. Comparatively, 19.0% of Miragen Therapeutics shares are held by institutional investors. 7.7% of Biocept shares are held by company insiders. Comparatively, 44.4% of Miragen Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.


This table compares Biocept and Miragen Therapeutics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Biocept -426.48% -374.92% -169.29%
Miragen Therapeutics -662.30% -63.57% -51.14%


Biocept beats Miragen Therapeutics on 8 of the 14 factors compared between the two stocks.

About Biocept

Biocept, Inc., an early stage molecular oncology diagnostics company, develops and commercializes proprietary circulating tumor cell (CTC) and circulating tumor DNA assays utilizing a standard blood sample. The company's cancer assays provide information to oncologists and other physicians that enable them to select personalized treatment for their patients who have been diagnosed with cancer based on molecular drivers. It offers assays for solid tumor indications, such as breast cancer, non-small cell lung cancer, small cell lung cancer, gastric cancer, colorectal cancer, prostate cancer, and melanoma. The company sells its cancer diagnostic assays directly to oncologists and other physicians at private and group practices, hospitals, and cancer centers in the United States, as well as markets its clinical trial and research services to pharmaceutical and biopharmaceutical companies, and clinical research organizations. Biocept, Inc. was founded in 1997 and is headquartered in San Diego, California.

About Miragen Therapeutics

Signal Genetics, Inc. is a commercial stage, molecular genetic diagnostic company. The Company is focused on providing diagnostic services that help physicians to make decisions concerning the care of cancer patients. The Company’s diagnostic service is the Myeloma Prognostic Risk Signature (MyPRS) test. The MyPRS test is a microarray-based gene expression profile (GEP), assay that measures the expression level of specific genes and groups of genes that are designed to predict an individual’s long-term clinical outcome/prognosis, giving a basis for personalized treatment options. The Company’s MyPRS test provides a whole-genomic expression profile of a patient’s multiple myeloma (MM). The Company offers MyPRS test in its laboratory located in Little Rock, Arkansas. The Company is licensed to sell its test in all 50 states.

Receive News & Ratings for Biocept Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biocept and related companies with's FREE daily email newsletter.

Leave a Reply